Early Astrocytic Dysfunction Is Associated with Mistuned Synapses as well as Anxiety and Depressive-Like Behavior in the AppNL-F Mouse Model of Alzheimer's Disease
- PMID: 38995780
- PMCID: PMC11307019
- DOI: 10.3233/JAD-231461
Early Astrocytic Dysfunction Is Associated with Mistuned Synapses as well as Anxiety and Depressive-Like Behavior in the AppNL-F Mouse Model of Alzheimer's Disease
Abstract
Background: Alzheimer's disease (AD) is the most common neurodegenerative disease. Unfortunately, efficient and affordable treatments are still lacking for this neurodegenerative disorder, it is therefore urgent to identify new pharmacological targets. Astrocytes are playing a crucial role in the tuning of synaptic transmission and several studies have pointed out severe astrocyte reactivity in AD. Reactive astrocytes show altered physiology and function, suggesting they could have a role in the early pathophysiology of AD.
Objective: We aimed to characterize early synaptic impairments in the AppNL-F knock-in mouse model of AD, especially to understand the contribution of astrocytes to early brain dysfunctions.
Methods: The AppNL-F mouse model carries two disease-causing mutations inserted in the amyloid precursor protein gene. This strain does not start to develop amyloid-β plaques until 9 months of age. Thanks to electrophysiology, we investigated synaptic function, at both neuronal and astrocytic levels, in 6-month-old animals and correlate the synaptic activity with emotional behavior.
Results: Electrophysiological recordings in the hippocampus revealed an overall synaptic mistuning at a pre-plaque stage of the pathology, associated to an intact social memory but a stronger depressive-like behavior. Astrocytes displayed a reactive-like morphology and a higher tonic GABA current compared to control mice. Interestingly, we here show that the synaptic impairments in hippocampal slices are partially corrected by a pre-treatment with the monoamine oxidase B blocker deprenyl or the fast-acting antidepressant ketamine (5 mg/kg).
Conclusions: We propose that reactive astrocytes can induce synaptic mistuning early in AD, before plaques deposition, and that these changes are associated with emotional symptoms.
Keywords: Alzheimer’s disease; App knock-in mice; LTP; MAO-B; depression; synapse.
Conflict of interest statement
The authors have no conflict of interest to report.
Figures







Similar articles
-
Reactive Astrocytes with Reduced Function of Glutamate Transporters in the AppNL-G-F Knock-in Mice.ACS Chem Neurosci. 2025 Jun 4;16(11):2035-2047. doi: 10.1021/acschemneuro.4c00714. Epub 2025 May 27. ACS Chem Neurosci. 2025. PMID: 40421586 Free PMC article.
-
Hippocampal disruptions of synaptic and astrocyte metabolism are primary events of early amyloid pathology in the 5xFAD mouse model of Alzheimer's disease.Cell Death Dis. 2021 Oct 16;12(11):954. doi: 10.1038/s41419-021-04237-y. Cell Death Dis. 2021. PMID: 34657143 Free PMC article.
-
Phagocytic clearance of presynaptic dystrophies by reactive astrocytes in Alzheimer's disease.Glia. 2018 Mar;66(3):637-653. doi: 10.1002/glia.23270. Epub 2017 Nov 27. Glia. 2018. PMID: 29178139 Free PMC article.
-
Hippocampal synaptic plasticity in Alzheimer's disease: what have we learned so far from transgenic models?Rev Neurosci. 2011;22(4):373-402. doi: 10.1515/RNS.2011.035. Epub 2011 Jul 6. Rev Neurosci. 2011. PMID: 21732714 Review.
-
Synaptic structure and function in transgenic APP mice.Ann N Y Acad Sci. 2000;924:39-41. doi: 10.1111/j.1749-6632.2000.tb05558.x. Ann N Y Acad Sci. 2000. PMID: 11193800 Review.
Cited by
-
A synapse perspective on the function of the amyloid precursor protein.Sci Prog. 2025 Jul-Sep;108(3):368504251360728. doi: 10.1177/00368504251360728. Epub 2025 Jul 30. Sci Prog. 2025. PMID: 40739894 Free PMC article. Review.
-
Ketamine does not rescue plaque load or gap detection in the 5XFAD mouse model of Alzheimer's disease.Front Aging Neurosci. 2025 Feb 3;17:1505908. doi: 10.3389/fnagi.2025.1505908. eCollection 2025. Front Aging Neurosci. 2025. PMID: 39963471 Free PMC article.
References
-
- Ferri CP, Sousa R, Albanese E, Ribeiro WS, MHonyashiki M, Acosta D, Blom M, Dudgeon S, Frantz N, Geiger A, Jensen A, Ketteringham A, Kinnaird L, Martensson B, Rees G, Schaper F, Splaine M, Tami T, Westerlind K, Wortmann M (2009) World Alzheimer’s Report 2009. Alzheimer’s Disease International, London.
-
- Shen LX, Yang YX, Kuo K, Li HQ, Chen SD, Chen KL, Dong Q, Tan L, Yu JT (2021) Social isolation, social interaction, and Alzheimer’s disease: A Mendelian randomization study. J Alzheimers Dis 80, 665–672. - PubMed
-
- Zubenko GS, Zubenko WN, McPherson S, Spoor E, Marin DB, Farlow MR, Smith GE, Geda YE, Cummings JL, Petersen RC, Sunderland T (2003) A collaborative study of the emergence and clinical features of the major depressive syndrome of Alzheimer’s disease. Am J Psychiatry 160, 857–866. - PubMed
-
- van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, Froelich L, Katayama S, Sabbagh M, Vellas B, Watson D, Dhadda S, Irizarry M, Kramer LD, Iwatsubo T (2023) Lecanemab in early Alzheimer’s disease. N Engl J Med 388, 9–21. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical